Abiopharma

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

New Form 6-K - Quantum Biopharma Ltd. Filed: 2025-08-07 AccNo: 0001171843-25-005150 Size: 30 KB

New Form 6-K - XORTX Therapeutics Inc. Filed: 2025-08-07 AccNo: 0001171843-25-005151 Size: 17 KB

New Form 6-K - ProQR Therapeutics N.V. Filed: 2025-08-07 AccNo: 0001558370-25-010635 Size: 3 MB

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Natera - Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Insulet - Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

Immunocore reports second quarter financial results and provides a business update

Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

ProQR Announces Second Quarter 2025 Operating and Financial Results

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates